SavedAdd your journal

Journals / Turkish Journal of Hematology / 2001 / Cilt: 18 - Sayı: 2

Hodgkin's disease: Results of a single center in central Anatolia

H. Şenol COŞKUN
Bülent ESER
Mustafa ÇETİN
Özlem ER
Ali ÜNAL
MUSTAFA ALTINBAŞ
Eray KARAHACIOĞLU
Bünyamin KAPLAN
Pages
117–121
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Five year survival rate was found as 70.8% of all patients, 90.1% for stage I-II, 55.3% for stage III-IV patients (p= 0.03).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hodgkin's Disease (HD) accounts for about 1% of newly diagnosed malignant diseases.
📊
Key Findings & Data:In this study 119 HD cases followed in Erciyes University Hospital were evaluated. 67.2% of the patients was male, 32.8% female.
💡
Conclusion & Impact:Five year survival rate was found as 70.8% of all patients, 90.1% for stage I-II, 55.3% for stage III-IV patients (p= 0.03).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Sağkalım · İlaç tedavisi · kombinasyon

Özet

Hodgkin's Disease (HD) accounts for about 1% of newly diagnosed malignant diseases. In this study 119 HD cases followed in Erciyes University Hospital were evaluated. 67.2% of the patients was male, 32.8% female. The patients' age ranged from 15 to 72 years with a median of 41.5 years. Of the patients 10.1% was stage I, 29.4% stage II, 39.5% stage III, and 21.0% stage IV. According to Rye classification frequency of histologic subtypes was as follows; 21.0% lymphocyte predominant, 25.2% nodular sclerosis, 43.7% mixed cellularity, and 10.1% lymphocyte depletion. Combination chemotherapy consisting cyclophosphamide, vincristine, procarbazine and prednisolone (COPP) was used as first line treatment in 59.7% of patients. Complete remission was achieved in 84.9% of patients and partial remission in 5.0% of patients; response could not be obtained in remaining 10.1% of patients. Disease progression or recurrence was observed in 30.2% of patients. Five year survival rate was found as 70.8% of all patients, 90.1% for stage I-II, 55.3% for stage III-IV patients (p= 0.03).

🔖

Cite This Article

COŞKUN, H. Ş., ESER, B., ÇETİN, M., ER, Ö., ÜNAL, A., ALTINBAŞ, M., KARAHACIOĞLU, E., KAPLAN, B. (2001). Hodgkin's disease: Results of a single center in central Anatolia. Turkish Journal of Hematology, Cilt: 18 - Sayı: 2, 117–121. https://ajindex.com/articles/413055

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rosen PJ, Lavey RS, Haskell CM. Hodgkin’s Disease In: Haskell CM (ed). Cancer treatment. 4th ed. Philadelphia. WB Saunder Company, 1995:951- 79
  2. DeVita VT, Mauch PM, Harris NL. Hodgkin’s Disease In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer Principles and Practice of Oncology. 5th ed. Philadelphia, Lippincoltt-Raven, 1997:2242-83
  3. Stein RS. Hodgkin Disease. In: Lee RG, Foerster J, Lukens J et al. (eds). Wintrobe’s Clinical Hematology. 10th ed. Egypt. Mass Pub. 1999:2538-71
  4. Medeiros LJ, Greiner TC. Hodgkin’s Disease. Cancer 1995;75(Suppl 1):357-69
  5. Bernhards J, Fischer R, Hubner K, Schwarze EW, Georgii A. Histopatological classification of Hodgkin’s lymphoma. Results from the reference pathology of the German Hodgkin’s trial. Ann Oncol 1992;3(Suppl 4):31-3
  6. Longo DL. The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol 1990;17: 716-35
  7. De Vita VT Jr, Simon RM, Hubbord SM, Young RC, Berard CW, Maxley JH, Frei ED 3d, Carbone PP, Canellos GP. Curability of advanced Hodgkin’s disease with chematherapy. Long-term follow-up of MOPP treated patients at the National Cancer Institue. Ann Intern Med 1980;92:587-95
  8. Longo DL, Young RC, Wesley M, Hubbord SM, Dufley PL, Jaffe ES, De Vita VT Jr. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 1986;4:1295-303
  9. Santora A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant in Hodgkin’s disease. Ann Intern Med 1982;96:139-43
  10. Nissen N, Nordentoft A,. Radiotherapy versus combined modality treatment of stage I and II Hodgkin’s disease. Cancer Tret Rep 1982;66:799-803
  11. Longo DL, Glatstein E, Duffey PL, Young RC, Hubbord SM, Urba WJ, Wesley MN, Routbitschek A, Jaffe ES, Wiernik PH. Radiotherapy versus combination chemotherapy in the treatment of early stage Hodgkin’s disease: Seven year results of a prospective randomized trial. J Clin Oncol 1991;9:906-17
  12. Sieber M, Ruffer U, Jostin A, Diehl V. Treatment of Hodgkin’s disease: Current strategies of the German Hodgkin’s Lymphoma Study Group. Ann Oncol 1999;10(Suppl 6):23-9
  13. Wolf J, Tesch H, Parsa-Parsi R, Engert A, Diehl V. Current clinical trials for the treatment of adult Hodgkin’s disease: Common strategies and perspectives. Ann Oncol 1989;9(Suppl 5):79-2
  14. Wolf J, Engert A, Diehl V. Issues in the treatment of Hodgkin’s disease. Curr Opin Oncol 1989;10:396- 402
  15. Advani RH, Horning SJ. Treatment of early-stage Hodgkin’s disease. Semin Hematol 1999;36:270- 81. 1